Enzo Biochem, Inc. (ENZ) Income Statement Analysis

See more : Reckitt Benckiser Group plc (RBGLY) Income Statement Analysis – Financial Results

Complete financial analysis of Enzo Biochem, Inc. (ENZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzo Biochem, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Enzo Biochem, Inc. (ENZ)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.enzo.com

About Enzo Biochem, Inc.

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986
Revenue	31.91M	31.06M	107.07M	117.73M	76.02M	81.17M	104.71M	107.80M	102.77M	97.60M	95.95M	93.71M	103.08M	102.03M	97.08M	89.57M	77.80M	52.91M	39.83M	43.40M	41.64M	52.77M	54.02M	58.41M	50.03M	44.30M	40.40M	34.90M	34.50M	31.70M	22.80M	20.00M	20.50M	19.80M	19.40M	12.10M	9.10M	8.70M	7.30M
Cost of Revenue	17.28M	19.50M	65.10M	64.15M	52.25M	57.92M	60.39M	59.48M	57.19M	54.77M	54.27M	54.84M	55.97M	53.82M	52.12M	53.06M	40.22M	23.23M	16.09M	14.74M	13.10M	11.78M	10.85M	17.42M	14.10M	14.30M	13.80M	13.80M	13.60M	12.10M	9.30M	6.70M	6.20M	21.20M	5.20M	3.60M	1.90M	1.70M	1.40M
Gross Profit	14.63M	11.57M	41.97M	53.58M	23.77M	23.25M	44.33M	48.33M	45.58M	42.83M	41.68M	38.87M	47.11M	48.21M	44.97M	36.51M	37.57M	29.68M	23.74M	28.66M	28.54M	40.99M	43.17M	40.98M	35.93M	30.00M	26.60M	21.10M	20.90M	19.60M	13.50M	13.30M	14.30M	-1.40M	14.20M	8.50M	7.20M	7.00M	5.90M
Gross Profit Ratio	45.86%	37.24%	39.20%	45.51%	31.27%	28.64%	42.33%	44.83%	44.35%	43.88%	43.44%	41.48%	45.70%	47.25%	46.32%	40.76%	48.30%	56.09%	59.60%	66.03%	68.53%	77.67%	79.92%	70.17%	71.81%	67.72%	65.84%	60.46%	60.58%	61.83%	59.21%	66.50%	69.76%	-7.07%	73.20%	70.25%	79.12%	80.46%	80.82%
Research & Development	2.64M	3.90M	3.77M	3.25M	4.45M	3.18M	3.21M	2.93M	3.52M	3.35M	3.14M	3.89M	6.29M	7.81M	9.70M	9.22M	8.64M	9.39M	7.90M	8.45M	8.08M	8.31M	6.18M	6.08M	5.43M	4.40M	4.00M	3.60M	3.10M	2.40M	1.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	24.36M	27.20M	53.71M	44.91M	49.69M	44.27M	44.47M	44.01M	43.59M	41.07M	41.80M	43.65M	51.65M	48.90M	52.09M	45.51M	43.72M	41.25M	35.99M	30.51M	32.69M	28.30M	28.00M	25.67M	23.49M	20.40M	19.90M	16.00M	17.50M	17.10M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	-2.63M	345.00K	577.00K	400.00K	437.00K	374.00K	580.00K	649.00K	601.00K	556.00K	440.00K	302.00K	237.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	21.72M	27.20M	53.71M	44.91M	42.96M	44.27M	44.47M	44.01M	43.59M	41.07M	41.80M	43.65M	51.65M	48.90M	52.09M	45.51M	43.72M	41.25M	35.99M	30.51M	32.69M	28.30M	28.00M	25.67M	23.49M	20.40M	19.90M	16.00M	17.50M	17.10M	10.60M	16.90M	12.90M	0.00	15.80M	12.20M	9.60M	9.60M	4.50M
Other Expenses	0.00	380.00K	-1.19M	6.91M	488.00K	382.00K	168.00K	125.00K	122.00K	95.00K	194.00K	5.00K	5.10M	4.43M	3.48M	5.84M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.93M	1.90M	1.90M	1.80M	1.80M	1.80M	1.50M	1.50M	700.00K	1.20M	500.00K	300.00K	0.00	500.00K	300.00K
Operating Expenses	27.00M	31.11M	57.47M	48.16M	47.41M	47.44M	51.37M	49.71M	49.45M	46.70M	48.01M	52.04M	63.05M	61.14M	65.28M	60.57M	52.36M	50.64M	43.89M	38.96M	40.77M	36.61M	34.18M	31.75M	30.84M	26.70M	25.80M	21.40M	22.40M	21.30M	13.90M	18.40M	13.60M	1.20M	16.30M	12.50M	10.10M	10.10M	4.80M
Cost & Expenses	44.27M	50.60M	122.58M	112.31M	99.66M	105.36M	111.75M	109.19M	106.64M	101.48M	102.27M	106.87M	119.02M	114.96M	117.39M	113.63M	92.58M	73.87M	59.98M	53.71M	53.88M	48.40M	45.03M	49.18M	44.94M	41.00M	39.60M	35.20M	36.00M	33.40M	23.20M	25.10M	19.80M	22.40M	21.50M	16.10M	12.00M	11.80M	6.20M
Interest Income	3.54M	0.00	178.00K	8.00K	454.00K	1.06M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	581.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	197.00K	0.00	159.00K	0.00	0.00	0.00	9.78M	2.58M	0.00	0.00	7.14M	11.52M	49.99M	0.00	3.92M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12.00M	0.00	0.00	2.70M	1.60M	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.27M	2.68M	2.83M	2.65M	2.78M	3.04M	3.13M	3.60M	3.84M	3.79M	3.97M	4.61M	4.48M	4.47M	4.27M	3.46M	2.15M	1.19M	1.12M	2.33M	2.36M	1.81M	2.15M	2.25M	1.93M	1.90M	1.90M	1.80M	1.80M	1.80M	1.50M	1.50M	700.00K	1.20M	500.00K	300.00K	500.00K	500.00K	300.00K
EBITDA	-8.35M	-20.94M	-15.01M	3.35M	-27.59M	-24.16M	-3.91M	1.09M	-6.56M	-1.21M	-5.73M	-14.29M	-11.46M	-8.35M	-17.99M	-20.02M	-8.75M	-19.78M	-19.03M	-7.97M	-9.87M	6.18M	11.14M	11.48M	7.01M	5.20M	2.70M	1.50M	300.00K	100.00K	1.10M	-3.60M	1.40M	-1.40M	-1.60M	-3.70M	-2.40M	-2.60M	1.40M
EBITDA Ratio	-26.16%	-39.01%	-10.23%	10.64%	-19.78%	100.00%	100.00%	100.00%	100.00%	-1.87%	1.26%	-3.02%	13.14%	-8.38%	-14.50%	-22.99%	-16.50%	-42.48%	-47.78%	-50.63%	-23.70%	11.71%	20.63%	19.66%	14.01%	11.74%	1.98%	-0.86%	18.26%	-35.65%	-6.14%	-13.00%	8.78%	16.67%	-19.59%	-61.16%	-59.34%	-67.82%	-9.59%
Operating Income	-9.82M	-24.74M	-15.51M	9.88M	-23.64M	78.13M	-12.16M	-3.07M	47.00M	-1.21M	-10.18M	-18.98M	-40.48M	-12.93M	-22.06M	-24.06M	-14.79M	-20.97M	-20.15M	-10.31M	-12.23M	4.37M	8.99M	9.23M	5.08M	3.30M	800.00K	-300.00K	-1.50M	-1.70M	-400.00K	-5.10M	700.00K	-2.60M	-2.10M	-4.00M	-2.90M	-3.10M	1.10M
Operating Income Ratio	-30.77%	-79.64%	-14.48%	8.39%	-31.09%	96.26%	-11.62%	-2.84%	45.73%	-1.24%	-10.61%	-20.25%	-39.27%	-12.67%	-22.72%	-26.86%	-19.01%	-39.63%	-50.60%	-23.74%	-29.37%	8.28%	16.64%	15.80%	10.16%	7.45%	1.98%	-0.86%	-4.35%	-5.36%	-1.75%	-25.50%	3.41%	-13.13%	-10.82%	-33.06%	-31.87%	-35.63%	15.07%
Total Other Income/Expenses	0.00	-286.00K	-3.31M	7.18M	1.85M	29.68M	746.00K	644.00K	56.92M	-1.09M	275.00K	31.00K	-442.00K	105.00K	-203.00K	-70.00K	3.89M	7.79M	3.14M	15.52M	1.15M	1.36M	1.35M	3.00M	2.58M	2.10M	1.80M	1.90M	-6.00M	11.40M	2.60M	-1.20M	-1.80M	2.60M	-1.80M	0.00	3.00M	-500.00K	1.00M
Income Before Tax	-9.82M	-25.02M	-18.26M	7.88M	-28.52M	2.49M	-11.42M	-2.42M	46.52M	-2.29M	-9.91M	-18.95M	-40.92M	-12.82M	-22.26M	-23.48M	-10.89M	-13.18M	-17.01M	5.22M	-11.08M	5.73M	10.34M	12.23M	7.67M	5.40M	2.60M	1.60M	-7.50M	9.70M	2.20M	-6.30M	-1.10M	-2.60M	-3.90M	-4.00M	100.00K	-3.60M	2.10M
Income Before Tax Ratio	-30.77%	-80.56%	-17.06%	6.69%	-37.52%	3.07%	-10.90%	-2.25%	45.26%	-2.35%	-10.32%	-20.22%	-39.70%	-12.57%	-22.93%	-26.21%	-14.00%	-24.90%	-42.71%	12.02%	-26.61%	10.85%	19.14%	20.94%	15.33%	12.19%	6.44%	4.58%	-21.74%	30.60%	9.65%	-31.50%	-5.37%	-13.13%	-20.10%	-33.06%	1.10%	-41.38%	28.77%
Income Tax Expense	0.00	12.30M	4.32M	4.45M	5.37M	101.27M	-1.10M	82.00K	1.23M	-7.00K	72.00K	-712.00K	-1.65M	137.00K	-28.00K	-87.00K	-239.00K	85.00K	-1.34M	2.21M	-4.85M	1.88M	3.42M	5.42M	1.04M	-1.10M	-800.00K	100.00K	200.00K	4.10M	-2.90M	100.00K	100.00K	12.90M	200.00K	100.00K	600.00K	-2.00M	600.00K
Net Income	-26.08M	20.29M	-22.58M	3.43M	-33.89M	-98.78M	-10.32M	-2.50M	45.29M	-2.29M	-9.98M	-18.24M	-39.27M	-12.96M	-22.23M	-23.56M	-10.65M	-13.26M	-15.67M	3.00M	-6.23M	3.84M	6.92M	6.81M	6.62M	6.50M	3.40M	1.50M	-7.70M	5.60M	5.30M	-6.90M	-600.00K	-10.80M	-4.10M	-4.10M	-3.50M	-1.60M	1.50M
Net Income Ratio	-81.73%	65.32%	-21.09%	2.91%	-44.58%	-121.70%	-9.86%	-2.32%	44.06%	-2.34%	-10.40%	-19.46%	-38.09%	-12.70%	-22.90%	-26.31%	-13.69%	-25.06%	-39.34%	6.92%	-14.96%	7.28%	12.82%	11.66%	13.24%	14.67%	8.42%	4.30%	-22.32%	17.67%	23.25%	-34.50%	-2.93%	-54.55%	-21.13%	-33.88%	-38.46%	-18.39%	20.55%
EPS	-0.51	-1.27	-0.46	0.07	-0.71	-2.09	-0.22	-0.05	0.98	-0.05	-0.23	-0.46	-1.01	-0.34	-0.59	-0.63	-0.29	-0.38	-0.49	0.09	-0.20	0.11	0.22	0.22	0.22	0.21	0.12	0.05	-0.27	0.19	0.19	-0.29	-0.03	-0.71	-0.26	-0.27	-0.24	-0.11	0.09
EPS Diluted	-0.51	-1.27	-0.46	0.07	-0.71	-2.08	-0.22	-0.05	0.97	-0.05	-0.23	-0.46	-1.01	-0.34	-0.59	-0.63	-0.29	-0.38	-0.49	0.09	-0.20	0.11	0.22	0.21	0.20	0.21	0.11	0.05	-0.27	0.19	0.18	-0.29	-0.03	-0.71	-0.26	-0.27	-0.24	-0.11	0.09
Weighted Avg Shares Out	50.90M	49.16M	48.59M	48.19M	47.70M	47.35M	46.91M	46.35M	46.15M	45.36M	42.56M	39.61M	38.80M	38.36M	38.00M	37.51M	36.88M	35.02M	32.22M	32.10M	31.70M	32.97M	31.36M	31.25M	30.79M	30.31M	29.97M	29.47M	28.84M	29.38M	28.05M	24.00M	18.26M	15.29M	15.60M	15.13M	14.69M	14.98M	16.60M
Weighted Avg Shares Out (Dil)	50.90M	49.16M	48.59M	48.33M	47.70M	47.48M	46.97M	46.35M	46.60M	45.36M	42.56M	39.61M	38.80M	38.36M	38.00M	37.51M	36.88M	35.02M	32.22M	32.76M	31.70M	33.78M	32.33M	32.56M	32.80M	30.97M	31.29M	29.47M	28.91M	29.38M	29.33M	24.00M	18.26M	15.29M	15.60M	15.13M	14.69M	14.98M	16.60M

Deutsche Bank AG Lowers Stock Holdings in Enzo Biochem, Inc. (NYSE:ENZ)

July 16, 2020thelincolnianonline.com

Deutsche Bank AG trimmed its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 35.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 13,731 shares of the medical research company’s stock after...

20 Healthcare Stocks Moving In Thursday's Pre-Market Session

July 16, 2020benzinga.com

Gainers • AC Immune, Inc. (NASDAQ:ACIU) shares rose 88.45% to $13.55 during Thursday's pre-market session. • Nabriva Therapeutics, Inc. (NASDAQ:NBRV) stock increased...

Coronavirus update: Global case tally edges toward 13 million, and Florida trounces one-day case record set by California last week

July 13, 2020marketwatch.com

The number of confirmed cases of the coronavirus illness COVID-19 worldwide edged closer to 13 million on Monday, a day after the World Health Organization...

Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2

July 13, 2020globenewswire.com

Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation

JPMorgan Chase & Co. Buys 39,331 Shares of Enzo Biochem, Inc. (NYSE:ENZ)

July 5, 2020thelincolnianonline.com

JPMorgan Chase & Co. lifted its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 151.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,293 shares of...